Oliver Politz

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Prostate Cancer

Signaling Pathway

Chronic Myeloid Leukemia

Combination Therapy

Top Venues

International journal of molecular sciences

Molecular cancer therapeutics

International journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Fabio Raith, Daniel H O'Donovan, Clara Lemos, Oliver Politz, Bernard Haendler
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment. International journal of molecular sciences 24 (3) (2023)
Fabio Raith, Daniel H O'Donovan, Clara Lemos, Oliver Politz, Bernard Haendler
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment. International journal of molecular sciences 24 (3) (2023)
Sabine Zitzmann-Kolbe, Alexander Kristian, Dieter Zopf, Claudia Kamfenkel, Oliver Politz, Christine Ellingsen, Jochen Hilbig, Mark U Juul, Jesper Fonslet, Carsten H Nielsen, Christoph A Schatz, Roger M Bjerke, Alan S Cuthbertson, Dominik Mumberg, Urs B Hagemann
A targeted thorium-227 conjugate demonstrates efficacy in preclinical models of acquired drug resistance and combination potential with chemotherapeutics and antiangiogenic therapies. Molecular cancer therapeutics (2023)
Fabio Raith, Daniel H O'Donovan, Clara Lemos, Oliver Politz, Bernard Haendler
Addressing the Reciprocal Crosstalk between the AR and the PI3K/AKT/mTOR Signaling Pathways for Prostate Cancer Treatment. International journal of molecular sciences 24 (3) (2023)
Alfonso García-Valverde, Jordi Rosell, Garazi Serna, Claudia Valverde, Joan Carles, Paolo G Nuciforo, Jonathan A Fletcher, Joaquín Arribas, Oliver Politz, César Serrano
Preclinical Activity of PI3K Inhibitor Copanlisib in Gastrointestinal Stromal Tumor. Molecular cancer therapeutics 19 (6) (2020)
Sylvia Grünewald, Oliver Politz, Sebastian Bender, Mélanie Héroult, Klemens Lustig, Uwe Thuss, Christoph Kneip, Charlotte Kopitz, Dieter Zopf, Marie-Pierre Collin, Ulf Boemer, Stuart Ince, Peter Ellinghaus, Dominik Mumberg, Holger Hess-Stumpp, Karl Ziegelbauer
Rogaratinib: A potent and selective pan-FGFR inhibitor with broad antitumor activity in FGFR-overexpressing preclinical cancer models. International journal of cancer 145 (5) (2019)